Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
$140.09
$0.29(0.21%)
At close: 4:00 PM EST
$140.09
$0.29(0.21%)
Day’s Range― - ―
52-Week Range$84.23 - $154.61
Previous CloseN/A
Volume209.65K
Average Volume (3M)831.14K
Market Cap
$13.89B
Enterprise Value$12.21B
Total Cash (Recent Filing)$975.60M
Total Debt (Recent Filing)$439.10M
Price to Earnings (P/E)41.4
Beta0.64
Next Earnings
Oct 28, 2025EPS Estimate
1.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.06
Shares Outstanding99,181,510
10 Day Avg. Volume723,554
30 Day Avg. Volume831,141
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)5.29
Price to Sales (P/S)5.82
P/FCF Ratio24.60
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue4.86
Enterprise Value/Gross Profit4.94
Enterprise Value/Ebitda21.91
Forecast
1Y Price Target
$168.76Price Target Upside20.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase II Savitri trial of osavampator showed positive results in patients with major depressive disorder who had an inadequate response to previous therapies.
Product LaunchThe Crenessity launch has been solid beating both the company's and investor expectations, and management is pleased with the performance so far.
Bears Say
Competitive PressureNeurocrine has been telegraphing a contracting headwind for Ingrezza, which was a surprise in the second quarter.
Market ChallengesOffice visits are a rate limiter to getting patients on Crenessity therapy, especially during slower summer periods.
Neurocrine News
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $84.23 and its highest was $154.61 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $13.89B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Oct 28, 2025 which is in 8 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Jul 30, 2025. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.965 by $0.095.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 1.59.
How many shares outstanding does Neurocrine have?
Neurocrine has 99,181,510 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.06 in its last earnings report, beating expectations of $0.965. Following the earnings report the stock price went down -6.237%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
Neurocrine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$168.76 (20.47% Upside)
$168.76 (20.47% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 663.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 14.0%
Last 30 Days ▲ 14.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.25%
12-Months-Change
Fundamentals
Return on Equity
13.39%
Trailing 12-Months
Asset Growth
17.69%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. (NBIX) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for neurological and endocrine diseases. Founded in 1992 and headquartered in San Diego, California, Neurocrine operates in the biopharmaceutical sector, with a focus on conditions such as movement disorders, psychiatric disorders, and endocrine diseases. The company’s core products include Ingrezza (valbenazine), which is approved for the treatment of tardive dyskinesia, and Ongentys (opicapone), used in Parkinson's disease management.
NBIX Company Deck
NBIX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and successful product launches, particularly with CRENESSITY and INGREZZA, alongside robust pipeline development. However, there are notable challenges such as the failure of the valbenazine study to meet its primary endpoint and pricing pressures on INGREZZA. Despite these challenges, the overall sentiment reflects confidence in continued growth and strategic investments.View all NBIX earnings summariesNBIX Stock 12 Month Forecast
Average Price Target
$168.76
▲(20.47% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
Amphastar Pharmaceuticals
―
Ownership Overview
1.10% Insiders
30.41% Mutual Funds
0.90% Other Institutional Investors
40.84% Public Companies and Individual Investors